Jacobs Levy Equity Management Inc. Sells 339,467 Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS)

Jacobs Levy Equity Management Inc. cut its stake in Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) by 37.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 576,042 shares of the biotechnology company's stock after selling 339,467 shares during the period. Jacobs Levy Equity Management Inc. owned 0.81% of Aclaris Therapeutics worth $1,429,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in ACRS. Assenagon Asset Management S.A. boosted its position in Aclaris Therapeutics by 113.9% during the 4th quarter. Assenagon Asset Management S.A. now owns 397,362 shares of the biotechnology company's stock valued at $985,000 after purchasing an additional 211,585 shares during the period. Peapod Lane Capital LLC acquired a new stake in shares of Aclaris Therapeutics during the fourth quarter worth $1,003,000. JPMorgan Chase & Co. boosted its position in shares of Aclaris Therapeutics by 942.0% in the 4th quarter. JPMorgan Chase & Co. now owns 88,320 shares of the biotechnology company's stock valued at $219,000 after purchasing an additional 79,844 shares during the period. Marshall Wace LLP purchased a new position in Aclaris Therapeutics in the 4th quarter worth about $6,532,000. Finally, Raymond James Financial Inc. acquired a new stake in Aclaris Therapeutics during the 4th quarter worth about $383,000. 98.34% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Scotiabank cut their price target on shares of Aclaris Therapeutics from $15.00 to $9.00 and set a "sector outperform" rating on the stock in a report on Friday, May 9th. StockNews.com downgraded shares of Aclaris Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, February 8th. HC Wainwright reiterated a "buy" rating and set a $16.00 price objective (down from $20.00) on shares of Aclaris Therapeutics in a report on Wednesday, May 14th. Finally, Cantor Fitzgerald started coverage on shares of Aclaris Therapeutics in a research report on Tuesday, March 18th. They issued an "overweight" rating for the company. One analyst has rated the stock with a sell rating, seven have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $10.00.

Aclaris Therapeutics Price Performance

Shares of NASDAQ ACRS traded up $0.05 during mid-day trading on Tuesday, hitting $1.35. The company had a trading volume of 487,036 shares, compared to its average volume of 1,179,337. Aclaris Therapeutics, Inc. has a 12 month low of $0.95 and a 12 month high of $5.17. The firm has a market cap of $146.18 million, a P/E ratio of -2.60 and a beta of 0.42. The business's 50-day simple moving average is $1.35 and its 200-day simple moving average is $2.23.

Aclaris Therapeutics (NASDAQ:ACRS - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.07. Aclaris Therapeutics had a negative net margin of 136.65% and a negative return on equity of 40.26%. As a group, sell-side analysts predict that Aclaris Therapeutics, Inc. will post -0.82 EPS for the current year.

Aclaris Therapeutics Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.